## PI3 Kinase p110 $\alpha$ (E542K)/p85 $\alpha$ , FLAG-Tag Recombinant

Catalog: 101913 Lot: 230808

**Product Information** 

**Description:** Recombinant human PI3 Kinase complex of p110 $\alpha$ , with an E542K mutation, and p85 $\alpha$ 

variant 1. Subunit p110 $\alpha$  encompasses amino acids 2-1068(end), and an N-terminal FLAG tag. Subunit p85 $\alpha$  encompasses amino acids 1-724(end). The two constructs were

expressed together, and the complex was affinity purified.

Background: PI3 (phosphoinositide 3) kinases, or phosphatidylinositol 3 kinases, are a family of

proteins that can be subdivided into four classes: I, II, III and IV. Class I is involved in converting PI (4, 5) P2 (phosphatidylinositol (4, 5)-biphosphate) into PI (3, 4, 5) P3 (phosphatidylinositol (3, 4, 5)-triphosphate) when activated by tyrosine kinase receptors and G-protein coupled receptors. They are heterodimeric proteins with a regulatory and a catalytic subunit. The heterodimer between p110 (catalytic subunit) and p85 (regulatory subunit) belongs to class IA. P110 and p85 have three variants each. P110 $\alpha$  is ubiquitously expressed, and p85 $\alpha$  is the most abundant variant of p85. Class I P13K participates in cell signaling, mostly via the activation of PKB (protein kinase B) and the P13K/AKT/mTOR pathway. Dysfunction of these kinases impacts cell growth and differentiation, and mutations in p110 $\alpha$  have been linked to cancer. At least three isoform-specific inhibitors are approved by FDA for the treatment of lymphoma and leukemia. Further studies will help identify more selective inhibitors with a good

tolerance that can bypass the development of drug resistance.

Species: Human

**Construct:** p110 $\alpha$  (E542K) (FLAG-2-1068(end)) / p85 $\alpha$  (1-724(end))

Mutation:p110α: E542KConcentration:1.54 mg/ml

Expression System: Sf9
Purity: ≥90%

**Format:** Aqueous buffer solution.

**Formulated In:** 25 mM Tris-HCl, pH 8.0, 69 mM NaCl, 1.3 mM KCl, 0.025% Tween-20, 50% glycerol, and

3 mM DTT

**MW:** p110α: 125 kDa; p85α: 84 kDa

**Genbank Accession:** p110α: NM\_006218; p85α: NM\_181523

**Stability:** At least 6 months at -80°C.

Storage: -80°C

**Instructions for Use:** Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before

opening. Aliquot into small volumes and flash freeze for long term storage. Avoid

multiple freeze/thaw cycles.

Assay Conditions: Assay was done according to Chemi-Verse™ PI3 Kinase p110α (E542K)/p85α Kinase

Assay Kit (BPS Bioscience #82113) with various concentrations of PI3 Kinase p110 $\alpha$ 

 $(E542K)/p85\alpha$ .

**Applications:** Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.

## PI3 Kinase p110 $\alpha$ (E542K)/p85 $\alpha$ , FLAG-Tag Recombinant

Catalog: 101913 Lot: 230808

**Quality Control Data** 

